NIMG-67. ADVANCED PERFUSION AND DIFFUSION MR IMAGING IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) AS FIRST-LINE THERAPY

Por Connelly, Jennifer M, Prah, Melissa A, Schmainda, Kathleen M
Publicado no Neuro Oncol (2017)

Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas

Por Ellingson, Benjamin M., Malkin, Mark G., Rand, Scott D., LaViolette, Pete S., Connelly, Jennifer M., Mueller, Wade M., Schmainda, Kathleen M.
Publicado em 2010

ACTR-44. AUTOPSY STUDY ON THE EFFECTS OF TUMOR TREATMENT FIELDS IN RECURRENT GLIOBLASTOMA: PRELIMINARY RESULTS AND TRIAL DESIGN

Por Hurrell, Sarah, Cochran, Elizabeth, McGarry, Sean, Connelly, Jennifer M, Schmainda, Kathleen M, Rand, Scott, Mueller, Wade M, LaViolette, Peter
Publicado no Neuro Oncol (2017)

Spatial Discrimination of Glioblastoma And Treatment Effect With Histologically-Validated Perfusion And Diffusion Magnetic Resonance Imaging Metrics

Por Prah, Melissa A, Al-Gizawiy, Mona M, Mueller, Wade M, Cochran, Elizabeth J, Hoffmann, Raymond G, Connelly, Jennifer M, Schmainda, Kathleen M
Publicado no J Neurooncol (2017)

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

Por Ellingson, Benjamin M., Malkin, Mark G., Rand, Scott D., Connelly, Jennifer M., Quinsey, Carolyn, LaViolette, Pete S., Bedekar, Devyani P., Schmainda, Kathleen M.
Publicado em 2010

Spatially Quantifying Microscopic Tumor Invasion and Proliferation Using a Voxel-Wise Solution to a Glioma Growth Model and Serial Diffusion MRI

Por Ellingson, Benjamin M., LaViolette, Peter S., Rand, Scott D., Malkin, Mark G., Connelly, Jennifer M., Mueller, Wade M., Prost, Robert W., Schmainda, Kathleen M.
Publicado em 2010

TMOD-08. IN VITRO PRE-TREATMENT OF CELL LINES PRODUCES A ROBUST IN VIVO XENOGRAFT MODEL MIMICKING RECURRENT GLIOBLASTOMA

Por Al-Gizawiy, Mona M, Wujek, Robert T, Alhajala, Hisham S, Doan, Ninh B, Knipstein, Jeffrey, Connelly, Jennifer M, Mirza, Shama P, Chitambar, Christopher R, Schmainda, Kathleen M
Publicado no Neuro Oncol (2017)

RARE-16. CASE REPORT: DELAYED DEVELOPMENT OF PSEUDOPROGRESSION IN 2 GLIOBLASTOMA PATIENTS TREATED WITH TTFIELDS

Por Hurrell, Sarah, Cochran, Elizabeth, Mueller, Wade M, McGarry, Sean, Schultz, Christopher J, Siker, Malika, Rand, Scott, LaViolette, Peter S, Schmainda, Kathleen M, Connelly, Jennifer M
Publicado no Neuro Oncol (2017)

Acid ceramidase confers radioresistance to glioblastoma cells

Por Doan, Ninh B., Nguyen, Ha S., Al-Gizawiy, Mona M., Mueller, Wade M., Sabbadini, Roger A., Rand, Scott D., Connelly, Jennifer M., Chitambar, Christopher R., Schmainda, Kathleen M., Mirza, Shama P.
Publicado no Oncol Rep (2017)

Acid ceramidase is a novel drug target for pediatric brain tumors

Por Doan, Ninh B., Nguyen, Ha S, Montoure, Andrew, Al-Gizawiy, Mona M., Mueller, Wade M., Kurpad, Shekar, Rand, Scott D., Connelly, Jennifer M., Chitambar, Christopher R., Schmainda, Kathleen M., Mirza, Shama P.
Publicado no Oncotarget (2017)

Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency

Por Doan, Ninh B., Alhajala, Hisham, Al-Gizawiy, Mona M., Mueller, Wade M., Rand, Scott D., Connelly, Jennifer M., Cochran, Elizabeth J., Chitambar, Christopher R., Clark, Paul, Kuo, John, Schmainda, Kathleen M., Mirza, Shama P.
Publicado no Oncotarget (2017)

Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics

Por Heroux, Maxime S., Chesnik, Marla A., Halligan, Brian D., Al-Gizawiy, Mona, Connelly, Jennifer M., Mueller, Wade M., Rand, Scott D., Cochran, Elizabeth J., LaViolette, Peter S., Malkin, Mark G., Schmainda, Kathleen M., Mirza, Shama P.
Publicado no Physiol Genomics (2014)